Description

Product Description

Glepaglutide (CAS 914009-86-2, ZP1848) is a synthetic long-acting glucagon-like peptide-2 (GLP-2) analogue that functions as a potent GLP-2 receptor agonist. By specifically targeting GLP-2 receptors, Glepaglutide exerts multiple physiological effects on the gastrointestinal tract. Its primary mechanism involves promoting intestinal epithelial proliferation, enhancing nutrient absorption, and reducing fecal output in preclinical models. These effects make Glepaglutide an indispensable tool for laboratory research on inflammatory bowel disease (IBD), Crohn’s disease, and related gastrointestinal disorders.

The compound’s long-acting nature ensures sustained receptor activation, allowing extended periods of intestinal mucosal regeneration and barrier restoration. This property is particularly valuable for preclinical studies examining intestinal morphology, villus height, crypt depth, and epithelial cell turnover. Furthermore, Glepaglutide has been shown to alleviate small intestinal inflammation by modulating immune responses, including downregulation of pro-inflammatory cytokines such as TNF-? and IL-6, while upregulating anti-inflammatory mediators.

Manufactured under GMP-certified conditions, Glepaglutide offers high purity (99.28%), ensuring batch-to-batch consistency and reliability for both wholesale and retail laboratory applications. The lyophilized powder maintains structural integrity during storage and transport, facilitating reproducible experimental results across research institutions.

Researchers employ Glepaglutide in a wide range of experimental contexts, including preclinical pharmacology, intestinal physiology, nutrient absorption studies, and mechanistic research on gastrointestinal disease progression. Its application extends to testing therapeutic hypotheses, evaluating combination treatments, and exploring the effects of GLP-2 receptor agonism on epithelial repair, barrier integrity, and inflammatory modulation.

By leveraging Glepaglutide, laboratories can investigate critical pathways involved in intestinal regeneration, immune modulation, and chronic gastrointestinal inflammation, advancing our understanding of IBD pathophysiology and informing the development of novel therapeutic strategies.

Disclaimer: For laboratory research use only, not for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Glepaglutide functions as a long-acting GLP-2 analogue that specifically activates the GLP-2 receptor (GLP-2R) on intestinal epithelial cells. Its key mechanisms include:

1. Promotion of intestinal epithelial proliferation: Increases villus height, crypt depth, and epithelial turnover.

2. Enhanced nutrient absorption: Improves macronutrient and micronutrient uptake by reducing fecal output and prolonging intestinal transit time.

3. Anti-inflammatory activity: Modulates inflammatory pathways by downregulating pro-inflammatory cytokines (e.g., TNF-?, IL-6) and upregulating anti-inflammatory mediators.

4. Mucosal barrier restoration: Enhances tight junction integrity and epithelial repair mechanisms, reducing intestinal permeability.

5. Long-acting receptor activation: Sustains GLP-2R signaling for extended biological effects, enabling studies of chronic intestinal regeneration.

These mechanisms render Glepaglutide ideal for studying gastrointestinal physiology, disease mechanisms, and preclinical therapeutic interventions in inflammatory bowel disease and Crohn’s disease.

Research Applications

1. Inflammatory Bowel Disease (IBD) Studies: Assess mucosal healing, epithelial regeneration, and inflammatory cytokine modulation in experimental IBD models.

2. Crohn’s Disease Research: Model small intestinal inflammation, study therapeutic efficacy, and evaluate GLP-2-mediated repair mechanisms.

3. Intestinal Absorption Studies: Quantify improvements in nutrient uptake, fecal output, and intestinal transit in preclinical models.

4. Small Intestinal Inflammation Research: Investigate molecular pathways of immune modulation, tissue repair, and mucosal recovery.

5. Pharmacodynamics and Pharmacokinetics: Study dose-response relationships, receptor activation kinetics, and long-acting peptide behavior.

6. Combination Therapy Models: Examine synergistic effects with other experimental peptides, anti-inflammatory compounds, or biologics.

7. Epithelial Barrier Function Studies: Assess tight junction proteins, mucosal integrity, and regenerative capacity after injury.

8. Molecular Mechanism Research: Explore GLP-2 receptor signaling, downstream intracellular pathways, and gene expression regulation.

9. Preclinical Gastrointestinal Physiology: Investigate villus morphology, crypt architecture, and epithelial turnover in normal and diseased states.

10. Translational Research Models: Evaluate potential interventions for human gastrointestinal disorders based on preclinical insights.

Glepaglutide’s versatility allows researchers to simulate clinical gastrointestinal disorders, examine therapeutic pathways, and generate mechanistic insights into intestinal regeneration and inflammation.

Side Effects (For Reference in Research Models)

In laboratory settings, Glepaglutide may demonstrate the following experimental effects:

• Altered intestinal motility: Reduced fecal output and modified transit time.

• Enhanced epithelial proliferation: Increased villus height, crypt depth, and mucosal regeneration.

• Immune modulation: Dose-dependent effects on pro-inflammatory and anti-inflammatory cytokine profiles.

• Morphological changes: Tissue remodeling and mucosal thickening observed in preclinical models.

• Dose-dependent receptor activation: Biological effects increase with higher concentrations in vitro or in vivo.

• Gastrointestinal physiology modulation: Changes in nutrient absorption, epithelial permeability, and barrier function.

Note: These effects are strictly for laboratory research and are not indicative of clinical safety or efficacy.

Disclaimer

Glepaglutide is supplied exclusively for laboratory research purposes. For laboratory research use only, not for human or veterinary use. It is not a dietary supplement or therapeutic agent. Proper laboratory safety protocols must always be followed.

Keywords

• Glepaglutide

• Glepaglutide CAS 914009-86-2

• ZP1848 peptide

• Long-acting GLP-2 analogue

• GLP-2 receptor agonist

• IBD research peptide

• Crohn’s disease laboratory research

• GMP peptide supplier Glepaglutide

• Intestinal absorption research

• Small intestine inflammation studies